Pharmaceutics (Jul 2022)

Effect of Lipid Composition on the Atheroprotective Properties of HDL-Mimicking Micelles

  • Kristen Hong,
  • Minzhi Yu,
  • Julia Crowther,
  • Ling Mei,
  • Karl Olsen,
  • Yonghong Luo,
  • Yuqing Eugene Chen,
  • Yanhong Guo,
  • Anna Schwendeman

DOI
https://doi.org/10.3390/pharmaceutics14081570
Journal volume & issue
Vol. 14, no. 8
p. 1570

Abstract

Read online

Atherosclerosis progression is driven by an imbalance of cholesterol and unresolved local inflammation in the arteries. The administration of recombinant apolipoprotein A-I (ApoA-I)-based high-density lipoprotein (HDL) nanoparticles has been used to reduce the size of atheroma and rescue inflammatory response in clinical studies. Because of the difficulty in producing large quantities of recombinant ApoA-I, here, we describe the preparation of phospholipid-based, ApoA-I-free micelles that structurally and functionally resemble HDL nanoparticles. Micelles were prepared using various phosphatidylcholine (PC) lipids combined with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000] (DSPE-PEG2k) to form nanoparticles of 15–30 nm in diameter. The impacts of PC composition and PEGylation on the anti-inflammatory activity, cholesterol efflux capacity, and cholesterol crystal dissolution potential of micelles were investigated in vitro. The effects of micelle composition on pharmacokinetics and cholesterol mobilization ability were evaluated in vivo in Sprague Dawley rats. The study shows that the composition of HDL-mimicking micelles impacts their overall atheroprotective properties and supports further investigation of micelles as a therapeutic for the treatment of atherosclerosis.

Keywords